At a glance

ClinicalIndex Comparison Record

Phase 2Completed· 10 enrolled

Drug / intervention

Botulinum Toxin Type A +1 moredrug

Likely dose

Botulinum Toxin Type A 40 unitsfrom record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02070302

NCT02070302Phase 2Completed

Compare CT.gov

BOTOX® (Onabotulinumtoxin A) Injection(s) as a Treatment for Carpal Tunnel Syndrome

Benjamin Sucher·interventional·Posted Feb 25, 2014·Updated Sep 27, 2017

In Brief

A Phase 2 clinical trial evaluating Botulinum Toxin Type A and Placebo for Carpal Tunnel Syndrome. Completed, enrolled 10 participants across 1 site.

Detailed Summary

This study will be a prospective double blind controlled randomized trial of ten patients diagnosed with Carpal Tunnel Syndrome (CTS). The study will be completed at offices of medical practices in Arizona. Patients who meet inclusion criteria will be randomly distributed into two groups: a BOTOX® (onabotulinumtoxin A) injection group and a Normal Saline Injection (NS) (Placebo group). Each group will consist of five randomly assigned individuals.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsCarpal Tunnel Syndrome

CountriesUnited States

CollaboratorsAllergan

Timeline

Phase 2CompletedFinished

2014201520162017201820192020202120222023202420252026

First PostedFeb 2014

Enrollment StartOct 2014

Primary CompletionFeb 2016

TodayJul 2026

First PostedFeb 25, 2014

Enrollment StartOct 1, 2014

Primary CompletionFeb 1, 2016

TodayJul 2, 2026

Enrollment to primary: 1.3 yearsPosted 12.4 years ago

Interventions

Botulinum Toxin Type Adrug

40 units of BOTOX® (onabotulinumtoxin A) divided into two injection sites of 20 units each

Placebodrug

Placebo (Normal Saline) divided into 2 injections of .4cc each